TY - JOUR T1 - Real-time monitoring of the effectiveness of six COVID-19 vaccines in Hungary in 2021 using the screening method JF - medRxiv DO - 10.1101/2022.02.18.22271179 SP - 2022.02.18.22271179 AU - Horváth J. Krisztina AU - Tamás Ferenci AU - Annamária Ferenczi AU - Gergő Túri AU - Gergely Röst AU - Beatrix Oroszi Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/19/2022.02.18.22271179.abstract N2 - Several studies have reported a waning of the effectiveness of COVID-19 vaccines. We report real-life vaccine effectiveness in Hungary, estimated with the screening method, in 2021, i.e., covering the dominance of both the Alpha and the Delta variant, and including the booster roll-out. Hungary is in the unique position to use six different vaccines (including the Sputnik V and Sinopharm vaccines, for which limited evidence was available prior to the present study) in the same, relatively homogeneous population. All vaccines provided high level of protection initially which declined over time. While the picture is different in each age group, the waning of immunity is apparent for all vaccines and especially in the younger age groups and the Sinopharm, Sputnik-V and AstraZeneca vaccines, which performed similarly. This is clearly reversed by booster doses, more prominent for those vaccines, where recipients were more likely to take the booster dose (which were the aforementioned three vaccines). Booster doses were almost exclusively mRNA vaccines. Overall, two vaccines, Pfizer/BioNTech and Moderna tend to produce the best results in all age groups, and even with waning taken into account.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any specific funding. The Mathematical Modelling and Epidemiology Task Force was supported by National Re-search, Development and Innovation Office (NKFIH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scientific and Research Ethics Committee of Medical Research Council gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is not publicly available, but the analysis script - with simulated data - is available at https://github.com/tamas-ferenci/VaccineEffectivenessEstimationScreeningSpline. https://github.com/tamas-ferenci/VaccineEffectivenessEstimationScreeningSpline ER -